Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Henriette
Henriette De Bod, Roodepoort ZA
| Patent application number | Description | Published |
|---|---|---|
| 20120041241 | OLIGOMERISATION OF OLEFINIC COMPOUNDS IN THE PRESENCE OF AN ACTIVATED OLIGOMERISATION CATALYST - This invention relates to the oligomerisation of olefinic compounds in the presence of an activated oligomerisation catalyst. The invention also extends to a particular manner for providing an activated oligomerisation catalyst. According to the present invention, there is provided a process for producing an oligomeric product by the oligomerisation of at least one olefinic compound, the process including (a) providing an activated oligomerisation catalyst by combining, in any order, iii) a source of chromium, ιv) a ligating compound of the formula (R | 02-16-2012 |
Henriette Draborg, Alleroed DK
| Patent application number | Description | Published |
|---|---|---|
| 20120122157 | Signal Peptide for Producing a Polypeptide - The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct. | 05-17-2012 |
Henriette Draborg, Frederikssund DK
| Patent application number | Description | Published |
|---|---|---|
| 20100021967 | Alpha Factor Signal Peptide For Producing a Polypeptide - The present invention relates to a method for producing a polypeptide comprising using a variant alpha factor signal peptide having a substitution in position 9 resulting in a substitution of an A to either T, S, H, I, F, E, or G. The invention further relate to nucleic acid constructs comprising a first nucleotide sequence encoding the variant signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising said nuclei acid construct. | 01-28-2010 |
Henriette Gourdeau, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20090062255 | TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO - The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof. | 03-05-2009 |
| 20090170837 | METHODS FOR TREATING RAS DRIVEN CANCER IN A SUBJECT - The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues. | 07-02-2009 |
| 20110028458 | INHIBITION OF CELL MIGRATION BY A FARNESYLATED DIBENZODIAZEPINONE - The invention relates to the discovery that dibenzodiazepinone analogues have cell migration inhibiting activities on neoplastic and endothelial cells. The migration of neoplastic cells from various tumor types, such as a glioma tumor that may comprise an EGF and/or PTEN mutation, or a Ras-, Raf, or EGFR-mediated tumor, may be inhibited when contacted by the dibenzodiazepinone analogues of the present invention. The invention includes methods for inhibiting migration of a cell in a subject, by contacting a cell with a dibenzodiazepinone analogue of the present invention. | 02-03-2011 |
Henriette Husum Bak-Jensen, Kobenhavn DK
| Patent application number | Description | Published |
|---|---|---|
| 20090118285 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA - The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential. | 05-07-2009 |
Henriette Van Praag, Baltimore, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080227829 | Neurogenic compounds - The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal. | 09-18-2008 |
Henriette Weber, Duesseldorf DE
| Patent application number | Description | Published |
|---|---|---|
| 20080312123 | HOLLOW BODY WITH A COMPARTMENT, CONTAINING A PORTION OF A WASHING, CLEANING OR RINSING AGENT - A process for producing a detergent portion, comprising the steps of forming one or more dimensionally stable hollow bodies comprising at least one compartment by injection moulding, providing one or more means for compartmentalizing the dimensionally stable hollow bodies, filling the compartment with at least one detersive formulation, and closing the compartment to form a partial or whole enclosure around the detersive formulation. | 12-18-2008 |
Henriette Woldum, Vojie DK
| Patent application number | Description | Published |
|---|---|---|
| 20110009350 | Oil-in-Water Formulation of Avermectins - Oil-in-water emulsion formulations (EW) of avermectins based on esters of fatty acids as solvent and the use of such formulations for the control of crop pests. | 01-13-2011 |